For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.
Bradley S. Stolshek, PharmD
Advertisement
Articles by Bradley S. Stolshek, PharmD
Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.
Advertisement
Latest Updated Articles
- Etanercept and Ustekinumab Dosing for Psoriasis and Psoriatic Arthritis
September 21st 2017
- Compliance and Cost of Biologic Therapies for Rheumatoid Arthritis
September 21st 2017
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
3
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
4
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
5